NCT00095901View on ClinicalTrials.gov

Capecitabine For Nasopharyngeal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Head and Neck Cancer
Interventions
DRUG

Capecitabine

Trial Locations (3)

60637-1470

University of Chicago Cancer Research Center, Chicago

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Roche Pharma AG

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT00095901 - Capecitabine For Nasopharyngeal Cancer | Biotech Hunter | Biotech Hunter